Garcia-Quetglas, E. (Emilio)
- Publications
- item.page.relationships.isContributorAdvisorOfPublication
- item.page.relationships.isContributorOfPublication
7 results
Search Results
Now showing 1 - 7 of 7
- Farmacología de antimicrobianos utilizados en el tratamiento de las infecciones graves por bacterias grampositivas(Sociedad Española de Quimioterapia, 2003) Garcia-Quetglas, E. (Emilio); Gil-Aldea, I. (I.); Sadaba, B. (Belén); Azanza, J.R. (José Ramón)Antimicrobials with specific activity against Gram-positive cocci (glycopeptides, oxazolidinones and streptogramins) have pharmacokinetic differences that are important to know. Linezolid and teicoplanin can be administered extravascularly due to their good bioavailability, allowing their use as sequential therapy in patients requiring prolonged treatment. All of these antimicrobials have an adequate distribution in extracellular tissues, even teicoplanin, due to the balance between the fraction that is bound and unbound to plasma proteins and its long terminal half-life. As the elimination of glycopeptides is almost exclusively renal, it is necessary to perform a posology adjustment in patients with renal failure. Quinupristin/dalfopristin and linezolid are metabolized by the liver, but CYP450 is only involved in streptogramin elimination
- Posibles indicaciones del tratamiento de las enfermedades autoinmunes con tacrolimus(Ediciones Universidad de Navarra, 2004) Fernandez-Gallego, V. (V.); Garcia-Quetglas, E. (Emilio); Sadaba, B. (Belén); Azanza, J.R. (José Ramón)Tacrolimus is an immunosuppressive drug used most successfully as a primary drug to suppress the rejection of transplants. Tacrolimus may also be useful as a novel therapy for autoimmune disease. There are various reports in the bibliography about the use of tacrolimus in the treatment of some autoimmune diseases: inflammatory bowel disease, autoimmune hepatitis, cutaneous, neurologic, renal, endocrine or eye disease. In this review of more than 130 papers, we discuss the rationale for the use of tacrolimus in autoimmune disease and report the clinical experience with the drug in the management of a variety of autoimmune diseases. But, although there are a lot questions that require future research (dose, duration of treatment, when to begin tacrolimus treatment, how to monitor it, etc.), there is also wide experience with tacrolimus in the treatment of this type of disease.
- PK/PD y desarrollo de nuevas formulaciones en el campo de los antimicrobianos(Sociedad Espanola de Quimioterapia, 2005) Garcia-Quetglas, E. (Emilio)
- Farmacología de los azoles(Elsevier España, 2007) Garcia-Quetglas, E. (Emilio); Sadaba, B. (Belén); Azanza, J.R. (José Ramón)Azole antifungals have different pharmacokinetic characteristics: complete oral absorption for Voriconazole, and to a lesser extent for fluconazole. The absorption of posaconazole and itraconazole increases with food intake. All of them have high tissue distribution with low plasma concentrations, especially low in the case of posaconazole and itraconazole. Posaconazole and itraconazole have high plasmatic protein binding and consequently both have a very low free fraction. Elimination of azole antifungals is through a metabolic pathway with CYP450 isoenzymes, and has a non linear pharmacokinetics with a high risk of interation with other drugs since azoles have the ability of CYP450 isoenzymes inhibition. Possibly the parameter that defines more precisely their efficacy is AUIC with an optimum value near 20, although cut-off values must be defined since some azoles may have difficulty to reach this value.
- Levofloxacino. Experiencia clínica en tratamientos de larga duración de infecciones osteoarticulares(Servicio de Publicaciones de la Universidad de Navarra, 2002) Muñoz, M.J. (M. J.); Garcia-Quetglas, E. (Emilio); Azanza, J.R. (José Ramón); Cárdenas, E. (E.); Valenti-Nin, J.R. (Juan Ramón)Se ha realizado un estudio con el fin de evaluar la eficacia y la tolerancia de la administración de larga duración de levofloxacino en el tratamiento de infecciones osteoarticulares. Se incluyeron 50 pacientes con una previsión inicial de realizar tratamiento antibiótico de duración superior a cuatro semanas, durante los años 1999-2001. El 46% de los pacientes eran varones y recibieron tratamiento con levofloxacino durante una media de 122,8 días. En el 83,7% de los pacientes evaluables (41/49 pacientes) la evolución fue satisfac- toria, por la desaparición o mejoría de la infección. Se realizaron controles médicos y analíticos seriados, sin objetivarse en ellos alte- raciones significativas. Cinco de los pacientes estudiados presenta- ron un total de 7 efectos adversos: molestias digestivas (3), micosis oral (1), petequias (1), parestesias (1) y erupción pruriginosa(1). En tres de ellos se suspendió el tratamiento por este motivo. Se concluye que levofloxacino es un fármaco eficaz y bien tolerado, por ello puede ser utilizado en el tratamiento de infecciones que requieran terapia prolongada.
- Relación entre estructura y función en los azoles(Sociedad Española de Quimioterapia, 2004) Garcia-Quetglas, E. (Emilio); Sadaba, B. (Belén); Azanza, J.R. (José Ramón)
- Voriconazol(Ediciones Universidad de Navarra, 2003) Ferrer, R.M. (R. M.); Ciria, M. (M.); Garcia-Quetglas, E. (Emilio); Gil-Aldea, I. (I.); Sadaba, B. (Belén); Azanza, J.R. (José Ramón)